The promise of antiangiogenic therapy for ovarian cancer.
Jazaeri
Amir A
AA
W. Norman Thornton Division of Gynecologic Oncology, University of Virginia, Charlottesville, VA, USA. aj2a@virginia.edu
Slack-Davis
Jill K
JK
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D005260:Female; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D039302:Integrin alphaVbeta3; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse